Ilse J. E. Kouijzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilse J. E. Kouijzer has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Ianthe Maat
Department of Medical Microbiology and Radboud Community for Infectious Diseases, Radboud University Medical Center , Nijmegen
5 shared publications- Jaap Ten Oever
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publications Chantal P. Bleeker-Rovers
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud university medical center, Nijmegen, The Netherlands
3 shared publicationsJaap Ten Oever
Department of Internal Medicine and Radboud Community for Infectious Diseases, Radboud university medical center, Nijmegen, the Netherlands
3 shared publicationsErik H J G Aarntzen
Department of Medical Imaging, Radboud University Medical Center , Nijmegen, Netherlands
2 shared publications- Erik H. J. G. Aarntzen
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
IV–Oral Antibiotic Switch in Streptococcal and Enterococcal Endocarditis: Evaluating ESC Versus WikiGuideline Criteria
Background: The 2023 European Society of Cardiology (ESC) guideline and the 2023 WikiGuideline both support intravenous (IV)–oral antibiotic switch in selected patients with infective endocarditis but apply different eligibility criteria. We aimed to assess hypothetical eligibility according to both guideline sets and to describe actual IV–oral switch practice at our center. Methods: In this retrospective observational study, adult patients with possible or definite streptococcal or enterococcal infective endocarditis treated between January 2024 and January 2026 were included. Eligibility for IV–oral switch was retrospectively assessed according to the original ESC criteria and WikiGuideline criteria using a predefined hypothetical switch date. Actual IV–oral switches performed in clinical practice and their clinical outcomes were described separately. Results: Ninety patients were included. Based on the original ESC criteria, two patients (2.2%) were hypothetically eligible for IV–oral switch, compared with 67 patients (74.4%) according to the WikiGuideline criteria. The principal reason for ESC ineligibility was the absence of repeat transesophageal echocardiography before the hypothetical switch date. In clinical practice, 22 patients (24.4%) underwent IV–oral switch. None of these patients fulfilled original ESC eligibility criteria, whereas all fulfilled the WikiGuideline criteria. Clinical outcomes of patients who underwent IV–oral switch are presented descriptively. Conclusions: In this retrospective cohort, hypothetical eligibility for IV–oral switch differed substantially depending on whether the ESC or WikiGuideline criteria were applied. At our center, local imaging practice accounted for most ESC ineligibility. Prospective studies are needed to determine which eligibility criteria and imaging approaches best identify patients who can safely undergo IV–oral switch.
Open AccessIV–Oral Antibiotic Switch in Streptococcal and Enterococcal Endocarditis: Evaluating ESC Versus WikiGuideline Criteria
Background: The 2023 European Society of Cardiology (ESC) guideline and the 2023 WikiGuideline both support intravenous (IV)–oral antibiotic switch in selected patients with infective endocarditis but apply different eligibility criteria. We aimed to assess hypothetical eligibility according to both guideline sets and to describe actual IV–oral switch practice at our center. Methods: In this retrospective observational study, adult patients with possible or definite streptococcal or enterococcal infective endocarditis treated between January 2024 and January 2026 were included. Eligibility for IV–oral switch was retrospectively assessed according to the original ESC criteria and WikiGuideline criteria using a predefined hypothetical switch date. Actual IV–oral switches performed in clinical practice and their clinical outcomes were described separately. Results: Ninety patients were included. Based on the original ESC criteria, two patients (2.2%) were hypothetically eligible for IV–oral switch, compared with 67 patients (74.4%) according to the WikiGuideline criteria. The principal reason for ESC ineligibility was the absence of repeat transesophageal echocardiography before the hypothetical switch date. In clinical practice, 22 patients (24.4%) underwent IV–oral switch. None of these patients fulfilled original ESC eligibility criteria, whereas all fulfilled the WikiGuideline criteria. Clinical outcomes of patients who underwent IV–oral switch are presented descriptively. Conclusions: In this retrospective cohort, hypothetical eligibility for IV–oral switch differed substantially depending on whether the ESC or WikiGuideline criteria were applied. At our center, local imaging practice accounted for most ESC ineligibility. Prospective studies are needed to determine which eligibility criteria and imaging approaches best identify patients who can safely undergo IV–oral switch.
- Open Access
- 15 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e745-e753
Routine Serial Follow-up Blood Cultures After a Negative Result Within 48 Hours of Methicillin-susceptible Staphylococcus aureus Bacteremia: Low Yield, High Cost
Background: Follow-up blood cultures (FUBCs) are essential in managing Staphylococcus aureus bacteremia (SAB). Skip phenomenon (SP), intermittent negative cultures despite ongoing bacteremia, occurs in 4%–13% of SAB patients and may lead to premature cessation of diagnostics and inappropriate treatment. Early SP, defined as negative FUBCs within 48 hours after index culture followed by subsequent positivity, is poorly characterized but concerning, as it can mask persistent bacteremia (PB) linked to worse outcomes. Methods: We conducted a cohort study at 2 Dutch hospitals, including adult SAB patients. Patients were categorized as having early clearance (EC), PB, or SP. Primary outcome was early SP prevalence, secondary outcomes included the proportion of potentially missed cases of PB when relying on 1 negative FUBC within 48 hours, reasons for obtaining FUBCs in early SP patients, and estimated costs of unnecessary FUBCs. Results: Among 1005 included SAB patients, 31 patients had early SP (3.1%). In 27 of these (87%), clinical condition prompted repeat FUBCs. If 1 negative FUBC within 48 hours was considered sufficient, 4 patients (1%) without clinical triggers would have been misclassified as EC, potentially missing PB. Potential cost savings from discontinuing FUBCs after 1 negative result within 48 hours were 13 513 USD per 100 patients. Conclusions: Early SP in SAB was uncommon. Clinically stable, afebrile patients without signs of metastatic infection and 1 negative FUBC within 48 hours have a very low risk of missed PB. A day-2 focused, clinically guided approach may reduce low-yield testing and costs, while maintaining patient safety.
- 15 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e745-e753
Open AccessRoutine Serial Follow-up Blood Cultures After a Negative Result Within 48 Hours of Methicillin-susceptible Staphylococcus aureus Bacteremia: Low Yield, High Cost
Background: Follow-up blood cultures (FUBCs) are essential in managing Staphylococcus aureus bacteremia (SAB). Skip phenomenon (SP), intermittent negative cultures despite ongoing bacteremia, occurs in 4%–13% of SAB patients and may lead to premature cessation of diagnostics and inappropriate treatment. Early SP, defined as negative FUBCs within 48 hours after index culture followed by subsequent positivity, is poorly characterized but concerning, as it can mask persistent bacteremia (PB) linked to worse outcomes. Methods: We conducted a cohort study at 2 Dutch hospitals, including adult SAB patients. Patients were categorized as having early clearance (EC), PB, or SP. Primary outcome was early SP prevalence, secondary outcomes included the proportion of potentially missed cases of PB when relying on 1 negative FUBC within 48 hours, reasons for obtaining FUBCs in early SP patients, and estimated costs of unnecessary FUBCs. Results: Among 1005 included SAB patients, 31 patients had early SP (3.1%). In 27 of these (87%), clinical condition prompted repeat FUBCs. If 1 negative FUBC within 48 hours was considered sufficient, 4 patients (1%) without clinical triggers would have been misclassified as EC, potentially missing PB. Potential cost savings from discontinuing FUBCs after 1 negative result within 48 hours were 13 513 USD per 100 patients. Conclusions: Early SP in SAB was uncommon. Clinically stable, afebrile patients without signs of metastatic infection and 1 negative FUBC within 48 hours have a very low risk of missed PB. A day-2 focused, clinically guided approach may reduce low-yield testing and costs, while maintaining patient safety.
- Open Access
- 2 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (15) , 1944
Radiomics with Clinical Data and [18F]FDG-PET for Differentiating Between Infected and Non-Infected Intracavitary Vascular (Endo)Grafts: A Proof-of-Concept Study
Objective: We evaluated the feasibility of a machine-learning (ML) model based on clinical features and radiomics from [18F]FDG PET/CT images to differentiate between infected and non-infected intracavitary vascular grafts and endografts (iVGEI). Methods: Three ML models were developed: one based on pre-treatment criteria to diagnose a vascular graft infection (“MAGIC-light features”), another using radiomics features from diagnostic [18F]FDG-PET scans, and a third combining both datasets. The training set included 92 patients (72 iVGEI-positive, 20 iVGEI-negative), and the external test set included 20 iVGEI-positive and 12 iVGEI-negative patients. The abdominal aorta and iliac arteries in the PET/CT scans were automatically segmented using SEQUOIA and TotalSegmentator and manually adjusted, extracting 96 radiomics features. The best-performing models for the MAGIC-light features and PET-radiomics features were selected from 343 unique models. Most relevant features were combined to test three final models using ROC analysis, accuracy, sensitivity, and specificity. Results: The combined model achieved the highest AUC in the test set (mean ± SD: 0.91 ± 0.02) compared with the MAGIC-light-only model (0.85 ± 0.06) and the PET-radiomics model (0.73 ± 0.03). The combined model also achieved a higher accuracy (0.91 vs. 0.82) than the diagnosis based on all the MAGIC criteria and a comparable sensitivity and specificity (0.70 and 1.00 vs. 0.76 and 0.92, respectively) while providing diagnostic information at the initial presentation. The AUC for the combined model was significantly higher than the PET-radiomics model (p = 0.02 in the bootstrap test), while other comparisons were not statistically significant. Conclusions: This study demonstrated the potential of ML models in supporting diagnostic decision making for iVGEI. A combined model using pre-treatment clinical features and PET-radiomics features showed high diagnostic performance and specificity, potentially reducing overtreatment and enhancing patient outcomes.
- 2 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (15) , 1944
Open AccessRadiomics with Clinical Data and [18F]FDG-PET for Differentiating Between Infected and Non-Infected Intracavitary Vascular (Endo)Grafts: A Proof-of-Concept Study
Objective: We evaluated the feasibility of a machine-learning (ML) model based on clinical features and radiomics from [18F]FDG PET/CT images to differentiate between infected and non-infected intracavitary vascular grafts and endografts (iVGEI). Methods: Three ML models were developed: one based on pre-treatment criteria to diagnose a vascular graft infection (“MAGIC-light features”), another using radiomics features from diagnostic [18F]FDG-PET scans, and a third combining both datasets. The training set included 92 patients (72 iVGEI-positive, 20 iVGEI-negative), and the external test set included 20 iVGEI-positive and 12 iVGEI-negative patients. The abdominal aorta and iliac arteries in the PET/CT scans were automatically segmented using SEQUOIA and TotalSegmentator and manually adjusted, extracting 96 radiomics features. The best-performing models for the MAGIC-light features and PET-radiomics features were selected from 343 unique models. Most relevant features were combined to test three final models using ROC analysis, accuracy, sensitivity, and specificity. Results: The combined model achieved the highest AUC in the test set (mean ± SD: 0.91 ± 0.02) compared with the MAGIC-light-only model (0.85 ± 0.06) and the PET-radiomics model (0.73 ± 0.03). The combined model also achieved a higher accuracy (0.91 vs. 0.82) than the diagnosis based on all the MAGIC criteria and a comparable sensitivity and specificity (0.70 and 1.00 vs. 0.76 and 0.92, respectively) while providing diagnostic information at the initial presentation. The AUC for the combined model was significantly higher than the PET-radiomics model (p = 0.02 in the bootstrap test), while other comparisons were not statistically significant. Conclusions: This study demonstrated the potential of ML models in supporting diagnostic decision making for iVGEI. A combined model using pre-treatment clinical features and PET-radiomics features showed high diagnostic performance and specificity, potentially reducing overtreatment and enhancing patient outcomes.
- Open Access
- 29 July 2025
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (11) , 1828-1838
Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document
- 29 July 2025
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (11) , 1828-1838
Open AccessTreatment and follow-up of vascular graft and endograft infection: Delphi consensus document
- Open Access
- 6 July 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 139, 109255
From losing control to regaining control: Patient experiences of care for Staphylococcus aureus bacteremia
- 6 July 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 139, 109255
Open AccessFrom losing control to regaining control: Patient experiences of care for Staphylococcus aureus bacteremia
- 17 June 2025
- Vol. 169
[Personalized management of Staphylococcus aureus bacteraemia: guidelines for optimal diagnostics and treatment].
Staphylococcus aureus bacteraemia requires personalized management, as a 'one-size-fits-all' approach is not suitable in this severe infection. Risk-stratification should be used to determine the additional diagnostic work-up needed to define the specific S. aureus diagnosis. To avoid over- and undertreatment, it is of importance to define a specific clinical diagnosis in this often complex and heterogeneous infection.
- 17 June 2025
- Vol. 169
[Personalized management of Staphylococcus aureus bacteraemia: guidelines for optimal diagnostics and treatment].
Staphylococcus aureus bacteraemia requires personalized management, as a 'one-size-fits-all' approach is not suitable in this severe infection. Risk-stratification should be used to determine the additional diagnostic work-up needed to define the specific S. aureus diagnosis. To avoid over- and undertreatment, it is of importance to define a specific clinical diagnosis in this often complex and heterogeneous infection.
- Open Access
- 13 September 2024
- Published by Springer Nature in npj Imaging
- Vol. 2 (1) , 1-5
The role of [18F]FDG-PET/CT in Staphylococcus aureus bacteremia: A clinical perspective
Staphylococcus aureus bacteremia (SAB) is a severe infectious disease with a heterogenous clinical presentation. To diagnose possible metastatic infection and to start early adequate management including antimicrobial treatment and adequate source control as soon as possible, guidelines recommend additional imaging such as [18F]FDG-PET/CT. In this clinical perspective, we describe the current evidence of [18F]FDG-PET/CT in SAB and we share our view on the value of [18F]FDG-PET/CT in specific SAB patients.
- 13 September 2024
- Published by Springer Nature in npj Imaging
- Vol. 2 (1) , 1-5
Open AccessThe role of [18F]FDG-PET/CT in Staphylococcus aureus bacteremia: A clinical perspective
Staphylococcus aureus bacteremia (SAB) is a severe infectious disease with a heterogenous clinical presentation. To diagnose possible metastatic infection and to start early adequate management including antimicrobial treatment and adequate source control as soon as possible, guidelines recommend additional imaging such as [18F]FDG-PET/CT. In this clinical perspective, we describe the current evidence of [18F]FDG-PET/CT in SAB and we share our view on the value of [18F]FDG-PET/CT in specific SAB patients.
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1) , ofad015
Postoperative Inflammation and Fever After Elective Aortic Valve and Aortic Root Replacement: A Retrospective Cohort Study
Fever after cardiac surgery is common. More knowledge of postoperative fever could lead to better patient selection for diagnostic work-up and empirical antibiotic treatment. We aimed to analyze the postoperative course of inflammation and fever after elective aortic valve and aortic root replacement. In a retrospective single-center cohort study, we included three groups of patients after elective cardiac surgery: aortic root with aortic valve replacement (Bentall procedure, from 2014 to 2021), valve sparing root replacement (VSRR, from 2014 to 2021), and isolated surgical aortic valve replacement (SAVR, from 2018 to 2021). Exclusion criteria were age p = 0.001). Seventeen patients had fever due to infection versus 202 with diagnoses of postoperative inflammation. In case of infection, fever was significantly higher (38.8 versus 38.4°C, p = 0.03), and both the number of days with fever and hospital admission duration were significantly longer. Postoperative fever is more often observed after Bentall procedure and VSRR compared to SAVR. In diagnoses of infection, there is a higher and prolonged fever.
- 1 January 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1) , ofad015
Open AccessPostoperative Inflammation and Fever After Elective Aortic Valve and Aortic Root Replacement: A Retrospective Cohort Study
Fever after cardiac surgery is common. More knowledge of postoperative fever could lead to better patient selection for diagnostic work-up and empirical antibiotic treatment. We aimed to analyze the postoperative course of inflammation and fever after elective aortic valve and aortic root replacement. In a retrospective single-center cohort study, we included three groups of patients after elective cardiac surgery: aortic root with aortic valve replacement (Bentall procedure, from 2014 to 2021), valve sparing root replacement (VSRR, from 2014 to 2021), and isolated surgical aortic valve replacement (SAVR, from 2018 to 2021). Exclusion criteria were age p = 0.001). Seventeen patients had fever due to infection versus 202 with diagnoses of postoperative inflammation. In case of infection, fever was significantly higher (38.8 versus 38.4°C, p = 0.03), and both the number of days with fever and hospital admission duration were significantly longer. Postoperative fever is more often observed after Bentall procedure and VSRR compared to SAVR. In diagnoses of infection, there is a higher and prolonged fever.
- Open Access
- 2 December 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (1)
Thoracic aortic vascular graft infection: outcome after conservative treatment without graft removal
OBJECTIVES: Surgical debridement with aortic graft removal is considered the preferred treatment for thoracic aortic vascular graft infection (VGI). Conservative treatment with antibiotics only is usually reserved for inoperable patients. Due to Outpatient Parenteral Antimicrobial Therapy (OPAT) and better understanding of the antibiotic impact on biofilms, long-term targeted antibiotic therapy without graft removal may be an alternative treatment option for selected thoracic aortic VGI patients. The aim of this case series was to evaluate the outcome in patients with thoracic aortic VGI who were treated without graft removal. METHODS: This single-centre retrospective cohort study evaluated patients with a thoracic aortic VGI diagnosed between 2008 and 2021 and who were treated without graft removal. The primary outcome parameter was the 6-month mortality rate after VGI diagnosis. Secondary outcome parameters were cure rates and relapse of infection. RESULTS: Twenty-four patients with thoracic aortic VGI who were managed without graft removal were identified. The mortality rate 6 months after VGI diagnosis was 8% (2/24); one of these deaths was infection related. The median antibiotic treatment duration was 13 months (interquartile range 15). A total of 16 patients (67%) were cured. No relapses occurred after a median of 24-month (interquartile range 32) follow-up. CONCLUSIONS: Intensive antibiotic treatment, without graft removal, may be a non-inferior option in patients with a thoracic aortic VGI who are not considered for surgery.
- 2 December 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (1)
Open AccessThoracic aortic vascular graft infection: outcome after conservative treatment without graft removal
OBJECTIVES: Surgical debridement with aortic graft removal is considered the preferred treatment for thoracic aortic vascular graft infection (VGI). Conservative treatment with antibiotics only is usually reserved for inoperable patients. Due to Outpatient Parenteral Antimicrobial Therapy (OPAT) and better understanding of the antibiotic impact on biofilms, long-term targeted antibiotic therapy without graft removal may be an alternative treatment option for selected thoracic aortic VGI patients. The aim of this case series was to evaluate the outcome in patients with thoracic aortic VGI who were treated without graft removal. METHODS: This single-centre retrospective cohort study evaluated patients with a thoracic aortic VGI diagnosed between 2008 and 2021 and who were treated without graft removal. The primary outcome parameter was the 6-month mortality rate after VGI diagnosis. Secondary outcome parameters were cure rates and relapse of infection. RESULTS: Twenty-four patients with thoracic aortic VGI who were managed without graft removal were identified. The mortality rate 6 months after VGI diagnosis was 8% (2/24); one of these deaths was infection related. The median antibiotic treatment duration was 13 months (interquartile range 15). A total of 16 patients (67%) were cured. No relapses occurred after a median of 24-month (interquartile range 32) follow-up. CONCLUSIONS: Intensive antibiotic treatment, without graft removal, may be a non-inferior option in patients with a thoracic aortic VGI who are not considered for surgery.
- Open Access
- 8 September 2022
- Published by Springer Nature in Infection
- Vol. 51 (3) , 743-747
Clinically unsuspected orthopedic implants during S. aureus bacteremia do not require additional diagnostic work-up
Purpose: To assess the likelihood of occult infection in patients with clinically unsuspected orthopedic implants during Staphylococcus aureus bacteremia (SAB). Methods: In a retrospective study in two Dutch hospitals, we included all patients with SAB between 2013 and 2020 with one or more orthopedic implants in whom [18F]FDG-PET/CT was performed. The primary outcome was the percentage of patients who had an orthopedic implant-related infection by S. aureus. We also compared clinical parameters in patients with clinically suspected and unsuspected implants. Results: Fifty-five of 191 (29%) orthopedic implants in 118 SAB patients included had clinical signs of infection. Of all 136 unsuspected implants, 5 (3%, all arthroplasties), showed increased [18F]FDG uptake around the prosthesis on [18F]FDG-PET/CT. The clinical course of these patients without clinically overt infection or relapse of bacteremia during follow-up of a median of 48 months (range 0–48), however, argued against prosthetic joint infection. Conclusion: Although orthopedic implants are evidently a risk factor for metastatic infection during SAB, the absence of clinical symptoms obviate the need of additional investigations or prolonged antibiotic treatment.
- 8 September 2022
- Published by Springer Nature in Infection
- Vol. 51 (3) , 743-747
Open AccessClinically unsuspected orthopedic implants during S. aureus bacteremia do not require additional diagnostic work-up
Purpose: To assess the likelihood of occult infection in patients with clinically unsuspected orthopedic implants during Staphylococcus aureus bacteremia (SAB). Methods: In a retrospective study in two Dutch hospitals, we included all patients with SAB between 2013 and 2020 with one or more orthopedic implants in whom [18F]FDG-PET/CT was performed. The primary outcome was the percentage of patients who had an orthopedic implant-related infection by S. aureus. We also compared clinical parameters in patients with clinically suspected and unsuspected implants. Results: Fifty-five of 191 (29%) orthopedic implants in 118 SAB patients included had clinical signs of infection. Of all 136 unsuspected implants, 5 (3%, all arthroplasties), showed increased [18F]FDG uptake around the prosthesis on [18F]FDG-PET/CT. The clinical course of these patients without clinically overt infection or relapse of bacteremia during follow-up of a median of 48 months (range 0–48), however, argued against prosthetic joint infection. Conclusion: Although orthopedic implants are evidently a risk factor for metastatic infection during SAB, the absence of clinical symptoms obviate the need of additional investigations or prolonged antibiotic treatment.